Graft-versus-host disease prophylaxis after transplantation: A network meta-analysis

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Ziakas, Panayiotis D ^a   Zervou, Fainareti N ^a   Zacharioudakis, Ioannis M ^a   Mylonakis, Eleftherios ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; CYCLOSPORIN A; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS; NONMYELOABLATIVE CONDITIONING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SIBLING; SYSTEMATIC REVIEW; ADVERSE EFFECTS; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ANTILYMPHOCYTE SERUM; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84915827759     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114735     Document Type: Article

References (69)

1. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, et al. (2012) The EBMT activity survey: 1990-2010. Bone Marrow Transplant 47: 906-923.
2. Pasquini MC, Wang Z, Horowitz MM, Gale RP (2010) 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl: 87-105.
3. Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, et al. (1995) Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 86: 813-818.
4. Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, et al. (2012) Diagnosis and management of acute graft-versus-host disease. Br J Haematol 158: 30-45.
5. Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, et al. (2014) Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 49: 168-173.
6. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343: d5928.
7. Ziakas PD, Kourbeti IS, Mylonakis E (2014) Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Clin Ther 36: 292-306 e291.
8. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
10. Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25: 3443-3457.
11. Kourbeti IS, Ziakas PD, Mylonakis E (2014) Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis 58: 1649-1657.
12. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, et al. (2008) What is "quality of evidence" and why is it important to clinicians? BMJ 336: 995-998.
13. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, et al. (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64: 383-394.
14. Hadjigeorgiou GM, Doxani C, Miligkos M, Ziakas P, Bakalos G, et al. (2013) A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. J Clin Pharm Ther 38: 433-439.
15. Lumley T (2002) Network meta-analysis for indirect treatment comparisons. Stat Med 21: 2313-2324.
16. Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50: 683-691.
17. Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331: 897-900.
18. Laupacis A, Sackett DL, Roberts RS (1988) An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318: 1728-1733.
19. Chatellier G, Zapletal E, Lemaitre D, Menard J, Degoulet P (1996) The number needed to treat: a clinically useful nomogram in its proper context. BMJ 312: 426-429.
20. Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, et al. (2014) The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood 123: 2017-2025.
21. Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, et al. (2012) A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 97: 1882-1889.
22. Martin PJ, Furlong T, Rowley SD, Pergam SA, Lloid M, et al. (2012) Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease. Biol Blood Marrow Transplant 18: 922-929.
23. Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, et al. (2010) A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 16: 937-947.
24. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, et al. (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10: 855-864.
25. Bacigalupo A, Lamparelli T, Milone G, Sormani MP, Ciceri F, et al. (2010) Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant 45: 385-391.
26. Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, et al. (2007) Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 109: 4582-4585.
27. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, et al. (2004) A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 34: 621-625.
28. Lee KH, Choi SJ, Lee JH, Kim S, Seol M, et al. (2004) Cyclosporine alone vs cyclosporine plus methotrexate for post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation: a randomized prospective study. Bone Marrow Transplant 34: 627-636.
29. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, et al. (2001) Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98: 2942-2947.
30. Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, et al. (2001) Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 28: 181-185.
31. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E (2000) Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 96: 2391-2398.
32. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, et al. (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96: 2062-2068.
33. Locatelli F, Bruno B, Zecca M, Van-Lint MT, McCann S, et al. (2000) Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 96: 1690-1697.
34. Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, et al. (2000) Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 6: 254-261.
35. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, et al. (1998) Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92: 2303-2314.
36. Zikos P, Van Lint MT, Frassoni F, Lamparelli T, Gualandi F, et al. (1998) Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood 91: 3503-3508.
37. Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, et al. (1997) Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 89: 3880-3887.
38. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, et al. (1993) Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329: 1225-1230.
39. Ramsay NK, Kersey JH, Robison LL, McGlave PB, Woods WG, et al. (1982) A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 306: 392-397.
40. Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, et al. (1985) Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 65: 1325-1334.
41. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, et al. (1986) Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68: 119-125.
42. Biggs JC, Atkinson K, Gillett E, Downs K, Concannon A, et al. (1986) A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation. Transplant Proc 18: 253-255.
43. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, et al. (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314: 729-735.
44. Ringden O, Backman L, Lonnqvist B, Heimdahl A, Lindholm A, et al. (1986) A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1: 41-51.
45. Storb R, Deeg HJ, Thomas ED, Appelbaum FR, Buckner CD, et al. (1985) Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 66: 698-702.
46. Torres A, Martinez F, Gomez P, Herrera C, Rojas R, et al. (1989) Cyclosporin A versus methotrexate, followed by rescue with folinic acid as prophylaxis of acute graft-versus-host disease after bone marrow transplantation. Blut 58: 63-68.
47. Mrsic M, Labar B, Bogdanic V, Nemet D, Pavletic Z, et al. (1990) Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 6: 137-141.
48. Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, et al. (1990) What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 76: 1037-1045.
49. Atkinson K, Biggs J, Concannon A, Dodds A, Young S, et al. (1991) A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus- host disease after HLA-identical sibling marrow transplantation for haematological malignancy. Aust N Z J Med 21: 850-856.
50. Doney KC, Weiden PL, Storb R, Thomas ED (1981) Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation 31: 141-143.
51. Weiden PL, Doney K, Storb R, Thomas ED (1979) Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation 27: 227-230.
52. Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, et al. (2012) Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47: 1459-1464.
53. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, et al. (2012) Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119: 296-307.
54. Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, et al. (2012) Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev 9: CD009159.
55. Bacigalupo A (2005) Antithymocyte globulin for prevention of graft-versus-host disease. Curr Opin Hematol 12: 457-462.
56. George B, Kerridge IH, Gilroy N, Huang G, Hertzberg MS, et al. (2012) A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group. Transpl Infect Dis 14: 141-148.
57. Shayani S, Palmer J, Stiller T, Liu X, Thomas SH, et al. (2013) Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 19: 298-304.
58. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, et al. (2008) Sirolimus is associated with venoocclusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 112: 4425-4431.
59. Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scime R, et al. (1998) Early treatment of acute graft-versus- host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 92: 2288-2293.
60. Weaver CH, Clift RA, Deeg HJ, Storb R, Appelbaum FR, et al. (1994) Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplant 14: 885-893.
61. Frassoni F, Bacigalupo A, Sessarego M, Gualandi F, Lamparelli T, et al. (1991) The dose of total body irradiation (TBI), and GvHD prophilaxis have a crucial role on relapse risk and survival after BMT for leukaemia. Bone Marrow Transplant 7 Suppl 2: 130.
62. Ruutu T, Hermans J, van Biezen A, Niederwieser D, Gratwohl A, et al. (1998) How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 22: 614-615.
63. Pinana JL, Valcarcel D, Fernandez-Aviles F, Martino R, Rovira M, et al. (2010) MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 45: 1449-1456.
64. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, et al. (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101: 1620-1629.
65. Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, et al. (2009) Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 43: 643-653.
66. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, et al. (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352: 1087-1092.
67. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, et al. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106: 2912-2919.
68. Omer AK, Ziakas PD, Anagnostou T, Coughlin E, Kourkoumpetis T, et al. (2013) Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol Blood Marrow Transplant 19: 1190-1196.
69. Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, et al. (2014) Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia.